The economic realities of erythropoiesis-stimulating agent therapy in kidney disease

Kidney International

Volumn 70, Issue SUPPL. 104, 2006, Pages

  Wish, J B ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anemia; Economics; Erythropoiesis stimulating agents; Medicare; Reimbursement

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; ERYTHROPOIESIS; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; MEDICARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 33751119005     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001972     Document Type: Article

References (15)

1. Eggers PW, Greer J, Jencks S. The use of health care financing administration data for the development of a quality improvement project on the treatment of anemia. Am J Kidney Dis 1994; 24: 247-254.
2. National Kidney Foundation. DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 37(Suppl 3): S192-S240.
3. Centers for Medicare & Medicaid Services. 2005 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality: Baltimore, MD; December 2005.
4. Pisoni RL. Erythropoietin therapy in Europe: results from the DOPPS. Contrib Neprhol 2002; 137: 396-402.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37(Suppl 1): S182-238.
6. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446.
7. Thamer M, Zhang Y, Kaufman J et al. Factors influencing the route of administration for epoetin treatment among hemodialysis patients in the United States. Am J Kidney Dis 2006; 48: 44-87.
8. Levin A. Preaching and practice: evidence-based medicine and the accountability of nephrologists within the health care system The implications and findings of the cost-saving potential of subcutaneous versus intravenous epoetin therapy (editorial). Am J Kidney Dis 2002; 40: 662-663.
9. U.S. Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2004, pp 79.
10. Wish J, Law AW, Schulman KL. Extended dosing with darbepoetin alfa in pre-dialysis chronic kidney disease appears to be limited to patients with low dose requirements. Am J Kidney Dis 2006; 47: A61.
11. Wish J, Law AW, Schulman KL. Extended intervals using epoetin alfa in pre-dialysis patients with chronic kidney disease appears to be limited to patients with low dose requirements. Am J Kidney Dis 2006; 47: A62.
12. Barron J, Mody S, Boudreaux M et al. Dosing distribution patterns and associated costs of erythropoietic agents in patients with pre-dialysis chronic kidney disease from three large managed care organizations. J Am Soc Nephrol 2005; 16: 547A.
13. Morreale A, Plowman B, DeLatre M et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004; 20: 381-395.
14. Agency for Healthcare Research and Quality. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patient undergoing cancer treatment. May 2006 available at http://effectivehealthcare.ahrq.gov/synthesize/ reports/final.cfm?Document=7&Topic=33 Accessed 1 July 2006.
15. Provenzano R, Bhaduri S, Tang L et al. Randomized, controlled trial of extended epoetin alfa dosing for the treatment of patients with the anemia of chronic kidney disease: Final results from the PROMPT study. J Am Soc Nephrol 2004; 15: 544A.